{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:24:22Z","timestamp":1792783462345,"version":"4.5.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"the Graduate Innovation Project of Bengbu Medical University","award":["Byycx25029"],"award-info":[{"award-number":["Byycx25029"]}]},{"name":"the Program for Young Backbone Teachers in Universities of Anhui Province","award":["JNFX2023031"],"award-info":[{"award-number":["JNFX2023031"]}]},{"name":"Longhu Talent Project of Bengbu Medical University","award":["LH250304004"],"award-info":[{"award-number":["LH250304004"]}]},{"name":"the 2025 Bengbu Medical University, Qilu Pharmaceutical Co., Ltd. Key Cooperative Clinical Research Grant","award":["BY-QLZDE021"],"award-info":[{"award-number":["BY-QLZDE021"]}],"id":[{"id":"https:\/\/ror.org\/0155cg005","id-type":"ROR","asserted-by":"crossref"}]},{"name":"the Key Program of Natural Science Research of Higher Education of Anhui Province","award":["2025AHGXZK31416"],"award-info":[{"award-number":["2025AHGXZK31416"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Updates Surg"],"DOI":"10.1007\/s13304-026-02857-7","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:02:28Z","timestamp":1790611348000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of adjuvant targeted therapy plus immunotherapy in hepatocellular carcinoma patients with high-risk recurrence factors after hepatectomy"],"prefix":"10.1007","author":[{"given":"Mengmeng","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingzhi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongran","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0957-3895","authenticated-orcid":false,"given":"Ming","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"4","key":"2857_CR1","first-page":"369","volume":"10","author":"BY Zhong","year":"2025","unstructured":"Zhong BY, Fan W, Guan JJ et al (2025) Combination locoregional and systemic therapies in hepatocellular carcinoma. The lancet. Gastroenterol Hepatol 10(4):369\u2013386","journal-title":"Gastroenterol Hepatol"},{"issue":"3","key":"2857_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin 74(3):229\u2013263","journal-title":"Cancer J Clin"},{"issue":"4","key":"2857_CR3","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41575-022-00704-9","volume":"20","author":"C Yang","year":"2023","unstructured":"Yang C, Zhang H, Zhang L et al (2023) Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 20(4):203\u2013222","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"43","key":"2857_CR4","doi-asserted-by":"publisher","first-page":"5804","DOI":"10.3748\/wjg.v29.i43.5804","volume":"29","author":"YB Zhang","year":"2023","unstructured":"Zhang YB, Yang G, Bu Y et al (2023) Development of a machine learning-based model for predicting risk of early postoperative recurrence of hepatocellular carcinoma. World J Gastroenterol 29(43):5804\u20135817","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2857_CR5","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/j.jhep.2024.06.018","volume":"81","author":"C Fuster-Anglada","year":"2024","unstructured":"Fuster-Anglada C, Mauro E, Ferrer-F\u00e0brega J et al (2024) Histological predictors of aggressive recurrence of hepatocellular carcinoma after liver resection. J Hepatol 81(6):995\u20131004","journal-title":"J Hepatol"},{"issue":"5","key":"2857_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.62347\/VPSW2871","volume":"16","author":"ZC Guo","year":"2026","unstructured":"Guo ZC, Li L, Yu ZN et al (2026) Preoperative nomogram for predicting microvascular invasion and stratifying recurrence risk in early-stage hepatocellular carcinoma. Am J cancer Res 16(5):1966\u20131976","journal-title":"Am J cancer Res"},{"key":"2857_CR7","doi-asserted-by":"publisher","first-page":"607722","DOI":"10.2147\/JHC.S607722","volume":"13","author":"K Jiang","year":"2026","unstructured":"Jiang K, Li J, Zhang D, Wang W, Chang J (2026) Comparable long-term survival after curative hepatectomy for solitary large (5\u201310 cm) versus giant (\u2265\u200910 cm) hepatocellular carcinoma: a retrospective study. J Hepatocell Carcinoma 13:607722","journal-title":"J hepatocellular carcinoma"},{"key":"2857_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2147\/JHC.S352480","volume":"9","author":"K Lin","year":"2022","unstructured":"Lin K, Wei F, Huang Q et al (2022) Postoperative adjuvant transarterial chemoembolization plus tyrosine kinase inhibitor for hepatocellular carcinoma: a multicentre retrospective study. J hepatocellular carcinoma 9:127\u2013140","journal-title":"J hepatocellular carcinoma"},{"issue":"13","key":"2857_CR9","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/S1470-2045(15)00198-9","volume":"16","author":"J Bruix","year":"2015","unstructured":"Bruix J, Takayama T, Mazzaferro V et al (2015) Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 16(13):1344\u20131354","journal-title":"Lancet Oncol"},{"issue":"3","key":"2857_CR10","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41571-021-00573-2","volume":"19","author":"JM Llovet","year":"2022","unstructured":"Llovet JM, Castet F, Heikenwalder M et al (2022) Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 19(3):151\u2013172","journal-title":"Nat Rev Clin Oncol"},{"key":"2857_CR11","doi-asserted-by":"publisher","first-page":"116749","DOI":"10.1016\/j.ejca.2026.116749","volume":"240","author":"PC Lee","year":"2026","unstructured":"Lee PC, Cortellini A, Stefanini B et al (2026) Determinants of long-term survival from atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. Eur J cancer (Oxford England: 1990) 240:116749","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"10415","key":"2857_CR12","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","volume":"402","author":"S Qin","year":"2023","unstructured":"Qin S, Chen M, Cheng AL et al (2023) Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial. Lancet (London England) 402(10415):1835\u20131847","journal-title":"Lancet (London England)"},{"key":"2857_CR13","doi-asserted-by":"crossref","unstructured":"Lu S, Zhang W, Li J et al (2026) Sintilimab (PD-1 inhibitor) plus lenvatinib as conversion therapy followed by sequential surgery (SILENSES) for advanced unresectable hepatocellular carcinoma: a phase II, expansion trial. Signal Transd Targeted Therapy 11(1)","DOI":"10.1038\/s41392-026-02708-2"},{"key":"2857_CR14","doi-asserted-by":"publisher","first-page":"1710602","DOI":"10.3389\/fonc.2025.1710602","volume":"15","author":"J Li","year":"2025","unstructured":"Li J, Sun Y, Liu Z et al (2025) Adjuvant tyrosine kinase inhibitors plus anti-PD-1 therapy reduce recurrence in high-risk hepatocellular carcinoma after resection. Front Oncol 15:1710602","journal-title":"Front Oncol"},{"issue":"2","key":"2857_CR15","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.3390\/curroncol30020132","volume":"30","author":"J Yang","year":"2023","unstructured":"Yang J, Jiang S, Chen Y, Zhang J, Deng Y (2023) Adjuvant ICIs plus targeted therapies reduce HCC recurrence after hepatectomy in patients with high risk of recurrence. Curr Oncol (Toronto Ont) 30(2):1708\u20131719","journal-title":"Curr Oncol (Toronto Ont)"},{"key":"2857_CR16","doi-asserted-by":"publisher","first-page":"599142","DOI":"10.2147\/JHC.S599142","volume":"13","author":"M Li","year":"2026","unstructured":"Li M, Jiang Y, Gong L et al (2026) Development and validation of a machine learning-based individualized model to predict tki benefit in postoperative recurrent HCC. J Hepatocellular Carcinoma 13:599142","journal-title":"J hepatocellular carcinoma"},{"issue":"5","key":"2857_CR17","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.surg.2010.10.001","volume":"149","author":"NN Rahbari","year":"2011","unstructured":"Rahbari NN, Garden OJ, Padbury R et al (2011) Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery 149(5):713\u2013724","journal-title":"Surgery"},{"issue":"6","key":"2857_CR18","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1016\/j.jhep.2026.01.006","volume":"84","author":"A Yopp","year":"2026","unstructured":"Yopp A, Chen M, Cheng AL et al (2026) Updated data from IMbrave050: adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma. J Hepatol 84(6):1102\u20131111","journal-title":"J Hepatol"},{"key":"2857_CR19","doi-asserted-by":"crossref","unstructured":"Takizawa D, Arai H, Shibasaki M et al (2026) Efficacy of lenvatinib as second-line therapy after atezolizumab plus bevacizumab for hepatocellular carcinoma. Curr Oncol (Toronto Ont) 33(3)","DOI":"10.3390\/curroncol33030159"},{"issue":"2","key":"2857_CR20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.21037\/jgo-2026-1-0023","volume":"17","author":"G Liu","year":"2026","unstructured":"Liu G, Guo C, Li X et al (2026) PD-1 inhibitors combined with tyrosine kinase inhibitors for conversion therapy in patients with unresectable hepatocellular carcinoma: a retrospective cohort study. J Gastrointest Oncol 17(2):76","journal-title":"J Gastrointest Oncol"},{"issue":"13","key":"2857_CR21","doi-asserted-by":"publisher","first-page":"e7415","DOI":"10.1002\/cam4.7415","volume":"13","author":"CA Lim","year":"2024","unstructured":"Lim CA, Amaro CP, Ding PQ, Cheung WY, Tam VC (2024) Outcomes of hepatocellular carcinoma patients treated in the lenvatinib and immunotherapy era (2018\u20132021) compared to the sorafenib era (2008\u20132018). Cancer Med 13(13):e7415","journal-title":"Cancer Med"},{"issue":"5","key":"2857_CR22","doi-asserted-by":"publisher","first-page":"317","DOI":"10.4174\/astr.2026.110.5.317","volume":"110","author":"M Choi","year":"2026","unstructured":"Choi M, Hwang S, Kaibori M, Jo M (2026) Prediction of microvascular invasion and post-resection prognosis using ADV, AFP-PIVKA-II, and MoRAL scores in hepatocellular carcinoma patients: an international multicenter cohort study with 9,061 patients. Ann Surg Treat Res 110(5):317\u2013330","journal-title":"Annals Surg Treat Res"},{"issue":"4","key":"2857_CR23","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.jhep.2023.01.011","volume":"78","author":"Y Liu","year":"2023","unstructured":"Liu Y, Xun Z, Ma K et al (2023) Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy. J Hepatol 78(4):770\u2013782","journal-title":"J Hepatol"},{"key":"2857_CR24","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.2147\/JHC.S518531","volume":"12","author":"J Yu","year":"2025","unstructured":"Yu J, Zhu Y, Zhao S, Li X (2025) Efficacy analysis of TACE combined with lenvatinib and pd-1 inhibitors in the treatment of hepatitis B virus-related unresectable hepatocellular carcinoma. J hepatocellular carcinoma 12:1407\u20131415","journal-title":"J hepatocellular carcinoma"},{"issue":"1","key":"2857_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1186\/s12885-025-14163-3","volume":"25","author":"SL Lu","year":"2025","unstructured":"Lu SL, Zhang QY, Zhao YQ et al (2025) C-reactive protein to albumin ratio combined with the Systemic Inflammatory Response Index predicts the prognosis of patients undergoing radical hepatectomy. BMC Cancer 25(1):784","journal-title":"BMC Cancer"},{"issue":"3","key":"2857_CR26","doi-asserted-by":"publisher","first-page":"66","DOI":"10.21037\/hbsn-24-489","volume":"15","author":"Q Kong","year":"2026","unstructured":"Kong Q, Yang J, Kong D et al (2026) Impact of metabolic dysfunction-associated steatotic liver disease on long-term prognosis in hepatocellular carcinoma patients undergoing hepatectomy. Hepatobiliary Surg Nutr 15(3):66","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"2","key":"2857_CR27","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1159\/000547725","volume":"15","author":"S Lin","year":"2026","unstructured":"Lin S, Song Z, Chen P et al (2026) Conversion therapy based on TACE\/HAIC-based treatment to improve the therapeutic effect of initially unresectable hepatocellular carcinoma. Liver cancer 15(2):254\u2013284","journal-title":"Liver cancer"},{"issue":"4","key":"2857_CR28","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000543994","volume":"14","author":"M Piao","year":"2025","unstructured":"Piao M, Li C, Huang Z et al (2025) Conversion surgery after immune checkpoint inhibitor-based combination therapy for initially unresectable hepatocellular carcinoma: a retrospective cohort study. Liver cancer 14(4):456\u2013473","journal-title":"Liver cancer"}],"container-title":["Updates in Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13304-026-02857-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13304-026-02857-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T04:14:26Z","timestamp":1790655266000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13304-026-02857-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":28,"alternative-id":["2857"],"URL":"https:\/\/doi.org\/10.1007\/s13304-026-02857-7","relation":{},"ISSN":["2038-131X","2038-3312"],"issn-type":[{"value":"2038-131X","type":"print"},{"value":"2038-3312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"28 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board of Bengbu Medical University (Approval Number: [2026] No. 398) for retrospective analysis.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient informed consent was waived because of the retrospective design of this study.","order":3,"name":"Ethics","label":"Informed consent","group":{"name":"EthicsHeading","label":"Declarations"}}]}}